Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study.

Abstract

Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma. Oral procaterol 50 micrograms b.d., procaterol 100 micrograms b.d., and terbutaline 5 mg t.i.d., were compared when given randomly in 1-week treatment periods. The best clinical effect was found with terbutaline. Both anti-asthmatic and tremorgenic effects of procaterol were dose-related. Procaterol appeared effective in the doses tested, and a twice daily regimen would appear to be suitable with this drug.

• Authors: R Dahl, H Harving, J Henriksen, K Rønne, P Schøler
• Journal: Allergy (Allergy) Vol. 40 Issue 7 Pg. 501-5 (Oct 1985) ISSN: 0105-4538 [Print] Denmark
• PMID: 2933998 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Ethanolamines
• Terbutaline
• Procaterol

Topics

• Adolescent
• Adult
• Aged
• Asthma (drug therapy, physiopathology)
• Clinical Trials as Topic
• Double-Blind Method
• Ethanolamines (adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Peak Expiratory Flow Rate
• Procaterol
• Terbutaline (adverse effects, therapeutic use)
• Tremor (chemically induced)